Vir Biotechnology, Inc.
VIRNASDAQHealthcare● Active
$8.45
$-0.20(-2.31%)
Market Cap$1.4B
P/E Ratio—
52W High$11.66
52W Low$4.155
Vir Biotechnology, Inc. (VIR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · VIR · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $68.56M | $74.20M | $86.18M | $1615.80M | $1095.41M |
| Cost of Revenue | $11.71M | $478.64M | $572.83M | $620.97M | $513.87M |
| Gross Profit | $56.85M | ($404.44M) | ($486.65M) | $994.83M | $581.54M |
| Gross Margin %(computed) | 82.92% | -545.03% | -564.69% | 61.57% | 53.09% |
| Operating Expenses | |||||
| R&D Expenses | $432.80M | $506.50M | $579.72M | $474.65M | $448.01M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $524.87M | $182.72M | $197.66M | $161.76M | $160.79M |
| Operating Income | ($468.02M) | ($587.16M) | ($684.30M) | $833.07M | $420.75M |
| Operating Margin %(computed) | -682.68% | -791.27% | -794.04% | 51.56% | 38.41% |
| Interest Income | $40.24M | $71.81M | $86.99M | $28.09M | $0.44M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($437.77M) | ($523.11M) | ($628.19M) | $754.28M | $549.80M |
| Income Tax Expense | $0.22M | ($1.15M) | ($13.08M) | $238.44M | $21.22M |
| Net Income | ($437.99M) | ($521.96M) | ($615.06M) | $515.84M | $528.58M |
| Net Margin %(computed) | -638.87% | -703.40% | -713.69% | 31.92% | 48.25% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.16 | $-3.83 | $-4.59 | $3.89 | $4.07 |
| Wtd Avg Shares | 138.52M | 136.25M | 134.13M | 132.61M | 129.88M |
| EBITDA | ($426.09M) | ($508.91M) | ($641.64M) | $839.85M | $426.56M |
| EBITDA Margin %(computed) | -621.52% | -685.82% | -744.53% | 51.98% | 38.94% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Vir Biotechnology, Inc. data
About Vir Biotechnology, Inc. (VIR) Income Statement
Vir Biotechnology, Inc. (VIR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, VIR reported revenue of $0.07B, gross profit of $0.06B (gross margin 82.92%), and net income of ($0.44B) — a net profit margin of -638.87%.
Frequently asked questions
VIR · 4 questionsVir Biotechnology, Inc. (VIR) reported revenue of $0.07B for 2025, down 7.6% year-over-year.
VIR revenueVIR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08